Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
BioOptics Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Xeris Pharmaceuticals Inc
(NQ:
XERS
)
2.720
+0.030 (+1.12%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Xeris Pharmaceuticals Inc
< Previous
1
2
3
4
Next >
Xeris Biopharma Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024
July 25, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Announces CEO Succession Plan
July 08, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement With Beta Bionics
May 06, 2024
Via
ACCESSWIRE
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 03, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024
June 03, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
May 30, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events
May 09, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
May 06, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
May 02, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 03, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
March 06, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
March 06, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
February 28, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference
February 05, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab
January 10, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 05, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Updates Its Outlook for 2023
January 04, 2024
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 27, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Reports Third Quarter 2023 Financial Results
November 09, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4 2023
October 16, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Announces Private Convertible Note Exchange Transactions
September 27, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris to Participate in the 2023 Cantor Global Healthcare Conference
September 14, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
August 28, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline
August 08, 2023
Dallas, Texas--(Newsfile Corp. - August 8, 2023) - Stonegate is pleased to announce the...
Via
Newsfile
Xeris Biopharma Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report Second Quarter 2023 Financial Results on August 8, 2023
August 01, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Ships One Millionth Gvoke® Unit
July 31, 2023
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.